Mike Derkacz

Biography

A biopharmaceutical executive with 25 years of commercial experience, Mike is an accomplished and highly successful leader, with deep expertise in launching new products, creating highly effective teams and focused organizational leadership. Prior to Braeburn, he was Senior Vice President and Head of Global CNS and Pain Therapeutic Areas for Teva Pharmaceuticals.During his tenure at Teva, Mike led the strategic development of the CNS and Pain therapeutic areas, advancing several clinical candidates, building market-leading brands and directing important corporate acquisitions to expand the CNS pipeline and sustain leadership in the market. He led the launch of Copaxone 40mg, considered one of the most successful product introductions in the multiple sclerosis category and within the industry. He joined Teva through the acquisition of Cephalon, where he served as Vice President, CNS Business unit. Previously at Cephalon, he was Vice President, Marketing for CNS responsible for the award-winning launch of Nuvigil, as well as managing the commercial development and lifecycle strategy for Provigil. 

Research Interest

 His research interest in Business and Development